Optimització en l’obtenció d’HuperTacrina–Tacrina pel tractament de la Malaltia d’Alzheimer (Part II)

Author

Canet Guillén, Júlia

Abstract

In 1906 Alzheimer's disease was discovered and nowadays it’s one of the diseases that involves the most of the oldest population in all over the world. Alzheimer’s disease is a neurodegenerative disorder which affects mainly the patient’s memory and it is expected to continuously grown in the next years affecting almost 135.5 million people in 2050. The main objective of this project is to continue with the research of a multitarget drugs for the treatment of this disease, in order to obtain a low toxicity drug candidate with high inhibition of both acetylcholinesterase and butyrylcholinesterase.
The present work describes the synthesis of a dual inhibitor candidate where a Tacrine unit (first drug approved by the FDA for the treatment of this disease, which was withdrawn due to cytotoxic effects) is attached to an HuperTacrine (a Tacrine and Huperzine A hybridized compound) by an alkyl chain.

Director

Puig de la Bellacasa Cazorla, Raimon
Borrell Bilbao, José Ignacio

Degree

IQS SE - Undergraduate Program in Chemistry

Date

2021-09-05